Inclusion of "pharmacist" on OTC label warnings supported by majority of cmte. members.
This article was originally published in The Tan Sheet
Executive Summary
"PHARMACIST" INCLUSION IN OTC LABEL WARNINGS endorsed by a majority of the members of FDA's Nonprescription Drugs Advisory Committee at a July 14 meeting in Bethesda, Md. Asked by the agency to discuss possible alternatives to the "Ask a Doctor Before Use" phrase suggested in FDA's proposed rule on OTC label reform, the committee members recommended a number of possible options, with "pharmacist" and "health care professional" receiving the most support. The group did not vote on the issue; NDAC Chairman Ralph D'Agostino, PhD, Boston University, instead polled individual members for their preferences.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC